Previously Reported was Oramed Pharmaceuticals’s largest revenue line in fiscal 2019, bringing in $2.91M of $2.70M (108%).
| Restatement | FY 2019 |
|---|---|
| Previously Reported | $2.91M |
| Restatement Adjustment | -$207.00K |
| Total | $2.70M |
Oramed Pharmaceuticals brought in $2.70M from its two revenue lines in fiscal 2019, the year ended August 31, 2019. Previously Reported was the largest at $2.91M (107.7%).
The total is net of Restatement Adjustment, which took $207.00K off revenue in fiscal 2019.
Oramed Pharmaceuticals (ORMP) reports its revenue by restatement. In fiscal 2019, Previously Reported was its largest revenue line, bringing in $2.91M (107.7% of the total).
Previously Reported was Oramed Pharmaceuticals' largest revenue line in fiscal 2019, bringing in $2.91M, or 107.7% of the $2.70M total across its two revenue lines.
Every figure comes from Oramed Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Oramed Pharmaceuticals gives it, and years follow its fiscal calendar.
Oramed Pharmaceuticals' revenue by restatement goes back to fiscal 2019, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.